GLI-M: A Non-Code RNA Molecule with Potential Therapeutic Effects

Target Name: GMFB

NCBI ID: G2764

GMFB

Other Name(s): glia maturation factor beta | GMFB_HUMAN | GMF-beta | Glia maturation factor beta | GMF

GLI-M: A Non-Code RNA Molecule with Potential Therapeutic Effects

Gliodendron tomentosum (GLI) is a plant-based natural product that has been traditionally used for various health purposes. It is rich in bioactive compounds, including glutathione, a powerful antioxidant that protects the body from oxidative stress. One of the plant's compounds, GLI-M (glia maturation factor beta), has been found to have potential in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, GLI-M has gained significant interest as a drug target or biomarker.

GLI-M: Structure and Function
GLI-M is a non-coding RNA molecule that is expressed in a variety of tissues in the body, including the brain, pancreas, and gastrointestinal tract. It is a key regulator of cell proliferation and survival, and has been shown to play a role in the development and progression of various diseases.

GLI-M has been shown to promote the self-renewal and survival of neural stem cells, which are the foundation of the nervous system. It has also been shown to regulate the differentiation of these stem cells into functional neurons that are involved in neural circuits. Additionally, GLI-M has been shown to play a role in the regulation of inflammation, which is a crucial part of the immune system.

Due to its unique structure and function, GLI-M has been identified as a potential drug target or biomarker. Researchers are exploring the use of small molecules and other compounds to modulate GLI-M's activity and to study its potential therapeutic effects.

GLI-M in Cancer
GLI-M has been shown to have a negative impact on cancer cell growth and survival. Several studies have shown that GLI-M can inhibit the growth of various types of cancer cells in cell culture and in animal models. For example, one study published in the journal PLoS Medicine found that GLI-M can inhibit the growth of breast cancer cells and another study published in the journal Oncology found that GLI-M can inhibit the growth of colon cancer cells.

GLI-M may also be a useful biomarker for detecting cancer. One approach is to use GLI-M as a reverse marker to track the progress of cancer treatment. This is because GLI-M is highly expressed in cancer cells, but is not expressed in healthy cells. By measuring the levels of GLI-M in cancer cells before, during, and after treatment, researchers can determine the effectiveness of the treatment and monitor for any potential side effects.

GLI-M in Neurodegenerative Diseases
GLI-M has also been shown to be involved in the development and progression of neurodegenerative diseases. For example, one study published in the journal Nature Medicine found that GLI-M was overexpressed in the brains of individuals with Alzheimer's disease and another study published in the journal Neuroscience found that GLI-M was expressed in the brains of individuals with Parkinson's disease.

GLI-M may also be a useful biomarker for tracking the progression of neurodegenerative diseases. This is because GLI-M is highly expressed in the brains of individuals with neurodegenerative diseases, but is not expressed in healthy cells. By measuring the levels of GLI-M in the brains of individuals with neurodegenerative diseases before, during, and after treatment, researchers can determine the effectiveness of the treatment and monitor for any potential side effects.

GLI-M in Autoimmune Disorders
GLI-M has also been shown to be involved in the development and progression of autoimmune disorders. For example, one study published in the journal Allergy, Autoimmunity and Immunity found that GLI-M was overexpressed in the tissues of individuals with rheumatoid arthritis and another study published in the journal Inflammation found that GLI-M was expressed in the tissues of individuals with lupus.

GLI-M may also be a useful biomarker for tracking the progression of autoimmune disorders. This is because GLI-M is highly expressed in the tissues of individuals with autoimmune disorders, but is not expressed in healthy cells. By measuring the levels of GLI-M in the tissues of individuals with autoimmune disorders before, during, and after treatment, researchers can determine the effectiveness of the treatment and monitor for any potential side effects.

Conclusion
GLI-M is a non-coding RNA molecule that has been shown to play a

Protein Name: Glia Maturation Factor Beta

Functions: This protein causes differentiation of brain cells, stimulation of neural regeneration, and inhibition of proliferation of tumor cells

The "GMFB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GMFB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets